My thoughts on the sp move.
As the US economy ticks along, CSL benefits. Also, investors are beginning to understand the benefits that will flow from the R&D spend in new product launches. Also, CSL is already embedded in China. as the Chinese middle class grows, CSL will get significant tail winds from that.
Combine good management, good products, good strategy, good R&D, drugs that are non discretioanry, what is there not to like about it?
HT1
CSL @117, page-11
-
- There are more pages in this discussion • 12 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add CSL (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$295.78 |
Change
1.650(0.56%) |
Mkt cap ! $143.2B | |||
| Open | High | Low | Value | Volume |
| $293.56 | $296.11 | $293.46 | $135.7M | 460.4K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 1268 | $295.32 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $295.85 | 33 | 1 |
View Market Depth
| Last trade - 16.10pm 11/10/2024 (20 minute delay) ? |
| CSL (ASX) Chart |